{"organizations": [], "uuid": "952f6bb5996a99653bf00bf16f4f7a4ca674237f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180521.html", "section_title": "Archive News &amp; Video for Monday, 21 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-nucala-study/brief-glaxosmithkline-says-nucala-study-reports-long-term-safety-data-consistent-exacerbation-reduction-improved-asthma-control-idUSFWN1SS01D", "country": "US", "domain_rank": 408, "title": "BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.968, "site_type": "news", "published": "2018-05-21T15:13:00.000+03:00", "replies_count": 0, "uuid": "952f6bb5996a99653bf00bf16f4f7a4ca674237f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-glaxosmithkline-says-nucala-study/brief-glaxosmithkline-says-nucala-study-reports-long-term-safety-data-consistent-exacerbation-reduction-improved-asthma-control-idUSFWN1SS01D", "ord_in_thread": 0, "title": "BRIEF-GlaxoSmithKline Says Nucala Study Reports Long-Term Safety Data, Consistent Exacerbation Reduction, Improved Asthma Control", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "glaxosmithkline plc", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "improved asthma control", "sentiment": "neutral"}, {"name": "nucala study reports long-term safety data", "sentiment": "neutral"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 21 (Reuters) - GlaxoSmithKline PLC:\n* NUCALA (MEPOLIZUMAB) STUDY REPORTS LONG-TERM SAFETY DATA, CONSISTENT EXACERBATION REDUCTION AND IMPROVED ASTHMA CONTROL\n* NEW STUDY SHOWED ONE THIRD OF PATIENTS HAD NO EXACERBATIONS ON LONG-TERM TREATMENT WITH NUCALA Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-21T15:13:00.000+03:00", "crawled": "2018-05-22T19:32:57.007+03:00", "highlightTitle": ""}